Stem definition | Drug id | CAS RN |
---|---|---|
antiulcer, benzimidazole derivatives | 4162 | 138530-94-6 |
Dose | Unit | Route |
---|---|---|
30 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 30, 2009 | FDA | TAKEDA PHARMS USA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic kidney disease | 808.63 | 13.54 | 426 | 31452 | 39345 | 50533901 |
Renal injury | 232.69 | 13.54 | 112 | 31766 | 8499 | 50564747 |
End stage renal disease | 229.17 | 13.54 | 98 | 31780 | 5639 | 50567607 |
Enthesopathy | 192.67 | 13.54 | 93 | 31785 | 7100 | 50566146 |
Tenosynovitis | 185.95 | 13.54 | 103 | 31775 | 10462 | 50562784 |
Blood parathyroid hormone decreased | 160.93 | 13.54 | 82 | 31796 | 7032 | 50566214 |
Tongue disorder | 154.43 | 13.54 | 87 | 31791 | 9129 | 50564117 |
Panniculitis | 149.92 | 13.54 | 83 | 31795 | 8420 | 50564826 |
Red blood cell sedimentation rate | 149.00 | 13.54 | 63 | 31815 | 3523 | 50569723 |
Blood pressure systolic increased | 146.96 | 13.54 | 144 | 31734 | 35305 | 50537941 |
Rheumatoid nodule | 140.57 | 13.54 | 92 | 31786 | 12643 | 50560603 |
Granuloma skin | 134.34 | 13.54 | 68 | 31810 | 5750 | 50567496 |
Tendonitis | 131.32 | 13.54 | 98 | 31780 | 16607 | 50556639 |
Skin necrosis | 131.04 | 13.54 | 83 | 31795 | 10784 | 50562462 |
Ulcer | 110.83 | 13.54 | 96 | 31782 | 20104 | 50553142 |
Alanine aminotransferase abnormal | 103.10 | 13.54 | 51 | 31827 | 4105 | 50569141 |
Fear of injection | 100.58 | 13.54 | 57 | 31821 | 6046 | 50567200 |
Skin ulcer | 89.78 | 13.54 | 111 | 31767 | 35207 | 50538039 |
Hypercalcaemia | 84.21 | 13.54 | 88 | 31790 | 23264 | 50549982 |
Incorrect product administration duration | 83.32 | 13.54 | 59 | 31819 | 9216 | 50564030 |
Inflammation | 82.68 | 13.54 | 137 | 31741 | 56775 | 50516471 |
Drug eruption | 78.13 | 13.54 | 85 | 31793 | 23521 | 50549725 |
Basal cell carcinoma | 77.13 | 13.54 | 84 | 31794 | 23272 | 50549974 |
Psoriatic arthropathy | 76.21 | 13.54 | 119 | 31759 | 46913 | 50526333 |
Total lung capacity increased | 75.46 | 13.54 | 25 | 31853 | 702 | 50572544 |
C-reactive protein abnormal | 73.26 | 13.54 | 89 | 31789 | 27720 | 50545526 |
Maternal exposure during pregnancy | 72.53 | 13.54 | 8 | 31870 | 159770 | 50413476 |
Rash pruritic | 66.58 | 13.54 | 113 | 31765 | 47733 | 50525513 |
Forced expiratory volume decreased | 61.72 | 13.54 | 37 | 31841 | 4357 | 50568889 |
Exposure during pregnancy | 60.52 | 13.54 | 4 | 31874 | 121011 | 50452235 |
Rebound acid hypersecretion | 59.08 | 13.54 | 17 | 31861 | 294 | 50572952 |
Completed suicide | 58.86 | 13.54 | 7 | 31871 | 131882 | 50441364 |
Peak expiratory flow rate decreased | 56.19 | 13.54 | 19 | 31859 | 569 | 50572677 |
Pemphigus | 54.56 | 13.54 | 6 | 31872 | 120160 | 50453086 |
Asthma | 51.52 | 13.54 | 148 | 31730 | 89189 | 50484057 |
Glossodynia | 47.20 | 13.54 | 8 | 31870 | 115561 | 50457685 |
Cervix neoplasm | 46.53 | 13.54 | 13 | 31865 | 201 | 50573045 |
Frustration tolerance decreased | 46.18 | 13.54 | 34 | 31844 | 5640 | 50567606 |
Drug interaction | 46.12 | 13.54 | 35 | 31843 | 199586 | 50373660 |
Headache | 45.09 | 13.54 | 502 | 31376 | 506033 | 50067213 |
Obstructive airways disorder | 44.35 | 13.54 | 52 | 31826 | 15600 | 50557646 |
Red blood cell sedimentation rate increased | 44.30 | 13.54 | 72 | 31806 | 29344 | 50543902 |
Loss of personal independence in daily activities | 43.27 | 13.54 | 119 | 31759 | 69931 | 50503315 |
Arteriovenous fistula occlusion | 43.24 | 13.54 | 14 | 31864 | 365 | 50572881 |
Arthritis | 42.78 | 13.54 | 136 | 31742 | 86585 | 50486661 |
Blue toe syndrome | 42.30 | 13.54 | 14 | 31864 | 392 | 50572854 |
Tubulointerstitial nephritis | 42.22 | 13.54 | 50 | 31828 | 15161 | 50558085 |
Sputum discoloured | 42.18 | 13.54 | 47 | 31831 | 13348 | 50559898 |
Renal failure | 41.90 | 13.54 | 155 | 31723 | 106478 | 50466768 |
Somatic delusion | 41.45 | 13.54 | 15 | 31863 | 551 | 50572695 |
Peripheral swelling | 41.36 | 13.54 | 246 | 31632 | 205690 | 50367556 |
Blood pressure fluctuation | 41.35 | 13.54 | 78 | 31800 | 35745 | 50537501 |
Erythema | 39.70 | 13.54 | 190 | 31688 | 146224 | 50427022 |
Joint injury | 39.35 | 13.54 | 58 | 31820 | 21731 | 50551515 |
Toxicity to various agents | 38.85 | 13.54 | 46 | 31832 | 212453 | 50360793 |
Drug specific antibody | 38.28 | 13.54 | 20 | 31858 | 1805 | 50571441 |
Chromaturia | 37.29 | 13.54 | 46 | 31832 | 14544 | 50558702 |
Endometriosis | 36.78 | 13.54 | 26 | 31852 | 4049 | 50569197 |
Faeces soft | 36.72 | 13.54 | 26 | 31852 | 4058 | 50569188 |
Hyponatraemia | 36.41 | 13.54 | 8 | 31870 | 96131 | 50477115 |
Thrombocytopenia | 35.54 | 13.54 | 18 | 31860 | 127655 | 50445591 |
Rhinorrhoea | 35.26 | 13.54 | 91 | 31787 | 51492 | 50521754 |
Granuloma | 34.86 | 13.54 | 27 | 31851 | 4831 | 50568415 |
Body temperature decreased | 34.57 | 13.54 | 47 | 31831 | 16348 | 50556898 |
Cough | 33.96 | 13.54 | 264 | 31614 | 241000 | 50332246 |
Respiration abnormal | 33.69 | 13.54 | 27 | 31851 | 5075 | 50568171 |
Musculoskeletal stiffness | 33.58 | 13.54 | 165 | 31713 | 128316 | 50444930 |
Systemic lupus erythematosus | 33.31 | 13.54 | 24 | 31854 | 140598 | 50432648 |
Lung diffusion test decreased | 33.19 | 13.54 | 13 | 31865 | 596 | 50572650 |
Swelling | 33.09 | 13.54 | 47 | 31831 | 200825 | 50372421 |
Pancytopenia | 31.81 | 13.54 | 7 | 31871 | 84023 | 50489223 |
Neutropenia | 31.60 | 13.54 | 28 | 31850 | 147937 | 50425309 |
Blood pressure diastolic decreased | 30.77 | 13.54 | 45 | 31833 | 16736 | 50556510 |
Drug tolerance | 30.05 | 13.54 | 25 | 31853 | 4951 | 50568295 |
Pulmonary thrombosis | 30.05 | 13.54 | 30 | 31848 | 7511 | 50565735 |
Bradycardia | 29.79 | 13.54 | 3 | 31875 | 64423 | 50508823 |
Central obesity | 29.76 | 13.54 | 14 | 31864 | 1008 | 50572238 |
Total lung capacity decreased | 29.54 | 13.54 | 15 | 31863 | 1276 | 50571970 |
Confusional state | 29.16 | 13.54 | 45 | 31833 | 185883 | 50387363 |
Hypertensive nephropathy | 28.49 | 13.54 | 11 | 31867 | 485 | 50572761 |
Gastrooesophageal reflux disease | 28.27 | 13.54 | 109 | 31769 | 76319 | 50496927 |
Hand deformity | 28.07 | 13.54 | 14 | 31864 | 100185 | 50473061 |
Bronchopulmonary aspergillosis allergic | 27.72 | 13.54 | 14 | 31864 | 1177 | 50572069 |
Dysphonia | 26.98 | 13.54 | 69 | 31809 | 38823 | 50534423 |
Therapeutic reaction time decreased | 26.05 | 13.54 | 14 | 31864 | 1338 | 50571908 |
Gastritis fungal | 25.77 | 13.54 | 7 | 31871 | 97 | 50573149 |
Death | 25.42 | 13.54 | 112 | 31766 | 325267 | 50247979 |
Forced vital capacity decreased | 24.69 | 13.54 | 12 | 31866 | 929 | 50572317 |
Aspartate aminotransferase increased | 24.69 | 13.54 | 106 | 31772 | 77892 | 50495354 |
Connective tissue inflammation | 24.54 | 13.54 | 6 | 31872 | 53 | 50573193 |
Cardiac arrest | 24.49 | 13.54 | 11 | 31867 | 83640 | 50489606 |
Defaecation disorder | 24.06 | 13.54 | 10 | 31868 | 535 | 50572711 |
Parotid gland enlargement | 24.03 | 13.54 | 11 | 31867 | 744 | 50572502 |
Gastrointestinal motility disorder | 23.86 | 13.54 | 21 | 31857 | 4488 | 50568758 |
Hepatic enzyme increased | 23.76 | 13.54 | 31 | 31847 | 137349 | 50435897 |
No adverse event | 23.73 | 13.54 | 60 | 31818 | 33518 | 50539728 |
Lung opacity | 23.61 | 13.54 | 15 | 31863 | 1958 | 50571288 |
Renal pain | 23.59 | 13.54 | 23 | 31855 | 5596 | 50567650 |
Urine odour abnormal | 22.57 | 13.54 | 22 | 31856 | 5351 | 50567895 |
Echocardiogram abnormal | 22.46 | 13.54 | 12 | 31866 | 1133 | 50572113 |
Peak expiratory flow rate abnormal | 22.44 | 13.54 | 6 | 31872 | 78 | 50573168 |
Gastric disorder | 22.15 | 13.54 | 54 | 31824 | 29494 | 50543752 |
Drug tolerance decreased | 22.00 | 13.54 | 28 | 31850 | 9132 | 50564114 |
Renal haemangioma | 22.00 | 13.54 | 5 | 31873 | 31 | 50573215 |
Crepitations | 21.63 | 13.54 | 23 | 31855 | 6196 | 50567050 |
Cardio-respiratory arrest | 21.41 | 13.54 | 4 | 31874 | 53888 | 50519358 |
Bladder disorder | 21.27 | 13.54 | 25 | 31853 | 7518 | 50565728 |
Abnormal faeces | 21.12 | 13.54 | 19 | 31859 | 4177 | 50569069 |
Abdominal pain | 20.85 | 13.54 | 234 | 31644 | 235994 | 50337252 |
Allergy to chemicals | 20.77 | 13.54 | 12 | 31866 | 1320 | 50571926 |
Regurgitation | 20.65 | 13.54 | 12 | 31866 | 1334 | 50571912 |
Rheumatoid lung | 20.58 | 13.54 | 15 | 31863 | 2450 | 50570796 |
Pericarditis | 20.57 | 13.54 | 12 | 31866 | 78677 | 50494569 |
Nephrogenic anaemia | 20.49 | 13.54 | 13 | 31865 | 1692 | 50571554 |
Parapsoriasis | 20.47 | 13.54 | 6 | 31872 | 111 | 50573135 |
Hyperkalaemia | 20.37 | 13.54 | 3 | 31875 | 48086 | 50525160 |
Depressed level of consciousness | 20.33 | 13.54 | 4 | 31874 | 51949 | 50521297 |
Acute kidney injury | 20.16 | 13.54 | 226 | 31652 | 227832 | 50345414 |
Respiratory failure | 19.77 | 13.54 | 17 | 31861 | 91164 | 50482082 |
Oropharyngeal pain | 19.66 | 13.54 | 99 | 31779 | 77702 | 50495544 |
Patella fracture | 19.57 | 13.54 | 13 | 31865 | 1829 | 50571417 |
Blood pressure systolic decreased | 19.57 | 13.54 | 21 | 31857 | 5718 | 50567528 |
Coma | 19.12 | 13.54 | 6 | 31872 | 56873 | 50516373 |
Musculoskeletal disorder | 19.06 | 13.54 | 37 | 31841 | 17312 | 50555934 |
Lung diffusion disorder | 18.92 | 13.54 | 5 | 31873 | 62 | 50573184 |
Nausea | 18.89 | 13.54 | 579 | 31299 | 704819 | 49868427 |
Brain hypoxia | 18.74 | 13.54 | 8 | 31870 | 458 | 50572788 |
Nocturia | 18.47 | 13.54 | 22 | 31856 | 6708 | 50566538 |
Electrocardiogram QT prolonged | 18.31 | 13.54 | 5 | 31873 | 51881 | 50521365 |
Carcinoid tumour | 18.30 | 13.54 | 7 | 31871 | 301 | 50572945 |
Dry throat | 18.28 | 13.54 | 20 | 31858 | 5564 | 50567682 |
Platelet count decreased | 18.18 | 13.54 | 22 | 31856 | 100704 | 50472542 |
Wound | 18.16 | 13.54 | 24 | 31854 | 105770 | 50467476 |
Antinuclear antibody positive | 18.04 | 13.54 | 21 | 31857 | 6251 | 50566995 |
Abdominal pain upper | 17.97 | 13.54 | 166 | 31712 | 159143 | 50414103 |
Cardiac failure | 17.97 | 13.54 | 13 | 31865 | 76027 | 50497219 |
Nephropathy | 17.51 | 13.54 | 19 | 31859 | 5239 | 50568007 |
Nasopharyngitis | 17.42 | 13.54 | 192 | 31686 | 192735 | 50380511 |
Alanine aminotransferase increased | 17.34 | 13.54 | 105 | 31773 | 88254 | 50484992 |
Disease progression | 17.23 | 13.54 | 21 | 31857 | 95845 | 50477401 |
Insomnia | 17.17 | 13.54 | 177 | 31701 | 174688 | 50398558 |
Neutrophil count decreased | 17.08 | 13.54 | 4 | 31874 | 46022 | 50527224 |
Blood pressure diastolic abnormal | 17.01 | 13.54 | 25 | 31853 | 9336 | 50563910 |
Influenza | 16.69 | 13.54 | 105 | 31773 | 89433 | 50483813 |
Pulmonary embolism | 16.53 | 13.54 | 24 | 31854 | 101680 | 50471566 |
Upper respiratory tract infection | 16.05 | 13.54 | 83 | 31795 | 65815 | 50507431 |
Dry mouth | 16 | 13.54 | 74 | 31804 | 56104 | 50517142 |
Therapy non-responder | 15.88 | 13.54 | 69 | 31809 | 50953 | 50522293 |
Nasal congestion | 15.81 | 13.54 | 69 | 31809 | 51051 | 50522195 |
Migraine | 15.76 | 13.54 | 91 | 31787 | 75189 | 50498057 |
Thoracic operation | 15.68 | 13.54 | 5 | 31873 | 124 | 50573122 |
Malignant neoplasm progression | 15.64 | 13.54 | 12 | 31866 | 68112 | 50505134 |
Knee deformity | 15.34 | 13.54 | 9 | 31869 | 1018 | 50572228 |
Impaired healing | 15.14 | 13.54 | 13 | 31865 | 69773 | 50503473 |
Pyrexia | 15.06 | 13.54 | 160 | 31718 | 380043 | 50193203 |
C-reactive protein increased | 15.01 | 13.54 | 82 | 31796 | 66392 | 50506854 |
Humidity intolerance | 14.92 | 13.54 | 6 | 31872 | 295 | 50572951 |
Suicide attempt | 14.83 | 13.54 | 7 | 31871 | 51725 | 50521521 |
Injection site oedema | 14.79 | 13.54 | 9 | 31869 | 1089 | 50572157 |
Blood test abnormal | 14.77 | 13.54 | 26 | 31852 | 11293 | 50561953 |
Mononeuropathy | 14.59 | 13.54 | 5 | 31873 | 156 | 50573090 |
Flail chest | 14.56 | 13.54 | 4 | 31874 | 58 | 50573188 |
Urinary tract disorder | 14.46 | 13.54 | 12 | 31866 | 2368 | 50570878 |
Muscle strain | 14.46 | 13.54 | 20 | 31858 | 7068 | 50566178 |
Hyperchlorhydria | 14.37 | 13.54 | 10 | 31868 | 1518 | 50571728 |
Heart rate decreased | 14.27 | 13.54 | 53 | 31825 | 36444 | 50536802 |
Lung perforation | 14.08 | 13.54 | 4 | 31874 | 66 | 50573180 |
Oral discomfort | 13.98 | 13.54 | 21 | 31857 | 7996 | 50565250 |
Mucosal inflammation | 13.92 | 13.54 | 4 | 31874 | 40138 | 50533108 |
Pharyngitis streptococcal | 13.86 | 13.54 | 22 | 31856 | 8786 | 50564460 |
International normalised ratio increased | 13.73 | 13.54 | 5 | 31873 | 43147 | 50530099 |
Diarrhoea | 13.64 | 13.54 | 475 | 31403 | 588001 | 49985245 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic kidney disease | 531.51 | 19.14 | 250 | 9200 | 36166 | 29528911 |
End stage renal disease | 226.44 | 19.14 | 87 | 9363 | 7577 | 29557500 |
Renal injury | 179.60 | 19.14 | 80 | 9370 | 10122 | 29554955 |
Tenosynovitis | 149.42 | 19.14 | 53 | 9397 | 3680 | 29561397 |
Enthesopathy | 145.49 | 19.14 | 52 | 9398 | 3691 | 29561386 |
C-reactive protein abnormal | 114.18 | 19.14 | 51 | 9399 | 6485 | 29558592 |
Tongue disorder | 113.63 | 19.14 | 46 | 9404 | 4590 | 29560487 |
Synovitis | 100.44 | 19.14 | 55 | 9395 | 10835 | 29554242 |
Tendonitis | 95.66 | 19.14 | 48 | 9402 | 7913 | 29557164 |
Alanine aminotransferase abnormal | 92.43 | 19.14 | 35 | 9415 | 2922 | 29562155 |
Psoriatic arthropathy | 85.18 | 19.14 | 55 | 9395 | 14636 | 29550441 |
Loss of personal independence in daily activities | 78.43 | 19.14 | 65 | 9385 | 25375 | 29539702 |
Drug intolerance | 52.86 | 19.14 | 71 | 9379 | 48308 | 29516769 |
Headache | 50.99 | 19.14 | 146 | 9304 | 173861 | 29391216 |
Occupational dermatitis | 49.48 | 19.14 | 10 | 9440 | 72 | 29565005 |
Treatment failure | 44.67 | 19.14 | 57 | 9393 | 36882 | 29528195 |
Red blood cell sedimentation rate | 43.04 | 19.14 | 13 | 9437 | 541 | 29564536 |
Inspiratory capacity abnormal | 41.89 | 19.14 | 9 | 9441 | 90 | 29564987 |
Incorrect product administration duration | 41.69 | 19.14 | 22 | 9428 | 4019 | 29561058 |
Oesophageal polyp | 41.44 | 19.14 | 8 | 9442 | 44 | 29565033 |
Nerve degeneration | 41.16 | 19.14 | 10 | 9440 | 179 | 29564898 |
Granuloma skin | 41.03 | 19.14 | 13 | 9437 | 635 | 29564442 |
Nephrogenic anaemia | 39.55 | 19.14 | 17 | 9433 | 1968 | 29563109 |
Occupational exposure to air contaminants | 39.45 | 19.14 | 9 | 9441 | 121 | 29564956 |
Blood parathyroid hormone decreased | 37.97 | 19.14 | 13 | 9437 | 811 | 29564266 |
Asthma | 37.45 | 19.14 | 50 | 9400 | 33799 | 29531278 |
Stiff person syndrome | 36.97 | 19.14 | 8 | 9442 | 83 | 29564994 |
Renal failure | 36.12 | 19.14 | 101 | 9349 | 118498 | 29446579 |
Drug hypersensitivity | 35.82 | 19.14 | 72 | 9378 | 68334 | 29496743 |
Mobility decreased | 34.72 | 19.14 | 42 | 9408 | 25738 | 29539339 |
Blood immunoglobulin E increased | 33.37 | 19.14 | 15 | 9435 | 1932 | 29563145 |
Airway remodelling | 33.15 | 19.14 | 8 | 9442 | 139 | 29564938 |
Drug interaction | 33.01 | 19.14 | 11 | 9439 | 197374 | 29367703 |
Panniculitis | 32.98 | 19.14 | 13 | 9437 | 1208 | 29563869 |
Neck pain | 32.29 | 19.14 | 37 | 9413 | 21410 | 29543667 |
Device dislocation | 31.39 | 19.14 | 19 | 9431 | 4508 | 29560569 |
Erythema | 29.82 | 19.14 | 71 | 9379 | 75535 | 29489542 |
Terminal insomnia | 29.16 | 19.14 | 9 | 9441 | 403 | 29564674 |
Rheumatoid nodule | 29.07 | 19.14 | 14 | 9436 | 2108 | 29562969 |
Micturition urgency | 29.07 | 19.14 | 19 | 9431 | 5154 | 29559923 |
Device malfunction | 28.86 | 19.14 | 23 | 9427 | 8484 | 29556593 |
Hypertensive nephropathy | 28.74 | 19.14 | 9 | 9441 | 423 | 29564654 |
Erythema of eyelid | 28.54 | 19.14 | 10 | 9440 | 668 | 29564409 |
Occupational exposure to product | 27.21 | 19.14 | 8 | 9442 | 303 | 29564774 |
Renal haemangioma | 27.21 | 19.14 | 5 | 9445 | 20 | 29565057 |
Renal neoplasm | 26.92 | 19.14 | 11 | 9439 | 1122 | 29563955 |
Renal mass | 26.83 | 19.14 | 12 | 9438 | 1528 | 29563549 |
Bone density decreased | 25.83 | 19.14 | 12 | 9438 | 1668 | 29563409 |
Aspartate aminotransferase increased | 25.64 | 19.14 | 58 | 9392 | 59667 | 29505410 |
Pain | 25.26 | 19.14 | 115 | 9335 | 171317 | 29393760 |
Acute kidney injury | 24.82 | 19.14 | 157 | 9293 | 265110 | 29299967 |
Dyspnoea at rest | 23.61 | 19.14 | 14 | 9436 | 3200 | 29561877 |
Therapy non-responder | 23.12 | 19.14 | 38 | 9412 | 30873 | 29534204 |
Abdominal rigidity | 22.81 | 19.14 | 10 | 9440 | 1214 | 29563863 |
Hip surgery | 22.70 | 19.14 | 9 | 9441 | 849 | 29564228 |
Contraindicated product administered | 21.77 | 19.14 | 28 | 9422 | 18238 | 29546839 |
Chronic kidney disease-mineral and bone disorder | 21.54 | 19.14 | 7 | 9443 | 371 | 29564706 |
Alanine aminotransferase increased | 21.14 | 19.14 | 60 | 9390 | 70884 | 29494193 |
Restrictive pulmonary disease | 20.57 | 19.14 | 9 | 9441 | 1087 | 29563990 |
Rebound acid hypersecretion | 20.25 | 19.14 | 5 | 9445 | 96 | 29564981 |
Blood pressure diastolic increased | 19.40 | 19.14 | 13 | 9437 | 3673 | 29561404 |
Dermatitis contact | 19.32 | 19.14 | 12 | 9438 | 2980 | 29562097 |
Neutropenia | 19.26 | 19.14 | 9 | 9441 | 131702 | 29433375 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Chronic kidney disease | 662.84 | 14.15 | 403 | 34197 | 57516 | 64406616 |
Tenosynovitis | 337.37 | 14.15 | 152 | 34448 | 11681 | 64452451 |
Enthesopathy | 333.87 | 14.15 | 142 | 34458 | 9496 | 64454636 |
Tongue disorder | 272.56 | 14.15 | 132 | 34468 | 11948 | 64452184 |
Tendonitis | 236.49 | 14.15 | 143 | 34457 | 20139 | 64443993 |
End stage renal disease | 228.92 | 14.15 | 112 | 34488 | 10363 | 64453769 |
Blood parathyroid hormone decreased | 211.15 | 14.15 | 95 | 34505 | 7271 | 64456861 |
Red blood cell sedimentation rate | 202.82 | 14.15 | 76 | 34524 | 3638 | 64460494 |
Panniculitis | 197.22 | 14.15 | 96 | 34504 | 8783 | 64455349 |
Rheumatoid nodule | 192.27 | 14.15 | 106 | 34494 | 12545 | 64451587 |
Alanine aminotransferase abnormal | 188.47 | 14.15 | 86 | 34514 | 6802 | 64457330 |
Granuloma skin | 182.62 | 14.15 | 81 | 34519 | 5993 | 64458139 |
Psoriatic arthropathy | 178.16 | 14.15 | 163 | 34437 | 43118 | 64421014 |
C-reactive protein abnormal | 167.96 | 14.15 | 133 | 34467 | 28914 | 64435218 |
Skin necrosis | 154.19 | 14.15 | 96 | 34504 | 14233 | 64449899 |
Renal injury | 147.67 | 14.15 | 96 | 34504 | 15333 | 64448799 |
Blood pressure systolic increased | 143.61 | 14.15 | 154 | 34446 | 49299 | 64414833 |
Ulcer | 136.64 | 14.15 | 107 | 34493 | 22883 | 64441249 |
Loss of personal independence in daily activities | 118.50 | 14.15 | 169 | 34431 | 72285 | 64391847 |
Fear of injection | 113.78 | 14.15 | 58 | 34542 | 5854 | 64458278 |
Skin ulcer | 103.85 | 14.15 | 123 | 34477 | 43851 | 64420281 |
Basal cell carcinoma | 102.02 | 14.15 | 103 | 34497 | 30735 | 64433397 |
Headache | 99.87 | 14.15 | 552 | 34048 | 528915 | 63935217 |
Inflammation | 94.76 | 14.15 | 144 | 34456 | 65156 | 64398976 |
Hypercalcaemia | 91.47 | 14.15 | 98 | 34502 | 31318 | 64432814 |
Drug interaction | 89.80 | 14.15 | 41 | 34559 | 362042 | 64102090 |
Rash pruritic | 89.61 | 14.15 | 131 | 34469 | 57273 | 64406859 |
Asthma | 85.69 | 14.15 | 170 | 34430 | 95055 | 64369077 |
Toxicity to various agents | 82.89 | 14.15 | 46 | 34554 | 363467 | 64100665 |
Total lung capacity increased | 80.06 | 14.15 | 25 | 34575 | 683 | 64463449 |
Drug eruption | 78.66 | 14.15 | 97 | 34503 | 36039 | 64428093 |
Erythema | 74.34 | 14.15 | 245 | 34355 | 186825 | 64277307 |
Peripheral swelling | 62.77 | 14.15 | 250 | 34350 | 208903 | 64255229 |
Peak expiratory flow rate decreased | 57.96 | 14.15 | 19 | 34581 | 609 | 64463523 |
Thrombocytopenia | 55.96 | 14.15 | 25 | 34575 | 223776 | 64240356 |
Drug abuse | 55.57 | 14.15 | 4 | 34596 | 132370 | 64331762 |
Forced expiratory volume decreased | 54.38 | 14.15 | 38 | 34562 | 6829 | 64457303 |
Synovitis | 53.79 | 14.15 | 145 | 34455 | 98945 | 64365187 |
Hyponatraemia | 53.27 | 14.15 | 8 | 34592 | 148331 | 64315801 |
Rhinorrhoea | 51.45 | 14.15 | 105 | 34495 | 59864 | 64404268 |
Aspartate aminotransferase increased | 51.27 | 14.15 | 161 | 34439 | 119627 | 64344505 |
Red blood cell sedimentation rate increased | 51.24 | 14.15 | 73 | 34527 | 31162 | 64432970 |
Neutropenia | 50.81 | 14.15 | 33 | 34567 | 239591 | 64224541 |
Cervix neoplasm | 50.13 | 14.15 | 13 | 34587 | 177 | 64463955 |
Drug hypersensitivity | 50.11 | 14.15 | 256 | 34344 | 237559 | 64226573 |
Drug intolerance | 48.80 | 14.15 | 215 | 34385 | 187777 | 64276355 |
Frustration tolerance decreased | 48.75 | 14.15 | 34 | 34566 | 6091 | 64458041 |
Endometriosis | 46.88 | 14.15 | 25 | 34575 | 2767 | 64461365 |
Blood pressure diastolic decreased | 45.55 | 14.15 | 58 | 34542 | 22243 | 64441889 |
Occupational dermatitis | 44.58 | 14.15 | 11 | 34589 | 121 | 64464011 |
Pancytopenia | 44.55 | 14.15 | 11 | 34589 | 143298 | 64320834 |
Joint injury | 44.24 | 14.15 | 58 | 34542 | 22889 | 64441243 |
Nephrogenic anaemia | 42.80 | 14.15 | 25 | 34575 | 3300 | 64460832 |
Multiple organ dysfunction syndrome | 42.75 | 14.15 | 3 | 34597 | 101410 | 64362722 |
Gastrooesophageal reflux disease | 42.46 | 14.15 | 119 | 34481 | 83024 | 64381108 |
Somatic delusion | 40.90 | 14.15 | 15 | 34585 | 675 | 64463457 |
Sputum discoloured | 40.58 | 14.15 | 49 | 34551 | 17807 | 64446325 |
Arteriovenous fistula occlusion | 40.36 | 14.15 | 14 | 34586 | 535 | 64463597 |
Blue toe syndrome | 39.65 | 14.15 | 14 | 34586 | 564 | 64463568 |
Drug specific antibody | 38.71 | 14.15 | 20 | 34580 | 2075 | 64462057 |
Alanine aminotransferase increased | 38.36 | 14.15 | 162 | 34438 | 138869 | 64325263 |
Rebound acid hypersecretion | 37.81 | 14.15 | 9 | 34591 | 84 | 64464048 |
Blood pressure fluctuation | 37.79 | 14.15 | 85 | 34515 | 51786 | 64412346 |
Maternal exposure during pregnancy | 37.25 | 14.15 | 4 | 34596 | 95880 | 64368252 |
Therapy non-responder | 36.32 | 14.15 | 97 | 34503 | 65802 | 64398330 |
Death | 36.24 | 14.15 | 135 | 34465 | 482570 | 63981562 |
Cardiac arrest | 35.77 | 14.15 | 19 | 34581 | 154045 | 64310087 |
Cough | 35.35 | 14.15 | 280 | 34320 | 301868 | 64162264 |
Fatigue | 34.86 | 14.15 | 579 | 34021 | 748151 | 63715981 |
Obstructive airways disorder | 34.85 | 14.15 | 52 | 34548 | 23133 | 64440999 |
Occupational exposure to air contaminants | 34.81 | 14.15 | 9 | 34591 | 121 | 64464011 |
Respiration abnormal | 34.53 | 14.15 | 28 | 34572 | 6287 | 64457845 |
Respiratory failure | 34.41 | 14.15 | 22 | 34578 | 161161 | 64302971 |
Arthritis | 34.34 | 14.15 | 111 | 34489 | 83703 | 64380429 |
Drug tolerance decreased | 34.05 | 14.15 | 29 | 34571 | 6969 | 64457163 |
Nasopharyngitis | 33.84 | 14.15 | 200 | 34400 | 195873 | 64268259 |
Cardio-respiratory arrest | 33.77 | 14.15 | 6 | 34594 | 98387 | 64365745 |
Granuloma | 33.30 | 14.15 | 28 | 34572 | 6613 | 64457519 |
Completed suicide | 33.20 | 14.15 | 43 | 34557 | 224371 | 64239761 |
Hyperkalaemia | 32.95 | 14.15 | 7 | 34593 | 101122 | 64363010 |
Inspiratory capacity abnormal | 32.84 | 14.15 | 8 | 34592 | 83 | 64464049 |
Dysphonia | 32.67 | 14.15 | 75 | 34525 | 46307 | 64417825 |
Nerve degeneration | 32.46 | 14.15 | 10 | 34590 | 261 | 64463871 |
Sepsis | 32.20 | 14.15 | 46 | 34554 | 230295 | 64233837 |
Faeces soft | 32.10 | 14.15 | 26 | 34574 | 5829 | 64458303 |
Oesophageal polyp | 30.83 | 14.15 | 7 | 34593 | 52 | 64464080 |
Coma | 30.82 | 14.15 | 5 | 34595 | 87610 | 64376522 |
Rhabdomyolysis | 30.61 | 14.15 | 6 | 34594 | 91720 | 64372412 |
Musculoskeletal stiffness | 30.50 | 14.15 | 139 | 34461 | 123067 | 64341065 |
Arthralgia | 30.16 | 14.15 | 366 | 34234 | 441894 | 64022238 |
Pulmonary thrombosis | 29.19 | 14.15 | 32 | 34568 | 10486 | 64453646 |
Platelet count decreased | 28.19 | 14.15 | 29 | 34571 | 167682 | 64296450 |
Neutrophil count decreased | 28.08 | 14.15 | 4 | 34596 | 77192 | 64386940 |
Depressed level of consciousness | 27.87 | 14.15 | 5 | 34595 | 81431 | 64382701 |
Hypertensive nephropathy | 27.82 | 14.15 | 12 | 34588 | 829 | 64463303 |
Total lung capacity decreased | 27.74 | 14.15 | 15 | 34585 | 1707 | 64462425 |
Nausea | 27.32 | 14.15 | 581 | 34019 | 785219 | 63678913 |
C-reactive protein increased | 27.27 | 14.15 | 112 | 34488 | 94797 | 64369335 |
Defaecation disorder | 27.20 | 14.15 | 10 | 34590 | 453 | 64463679 |
Cardiac failure | 27 | 14.15 | 19 | 34581 | 132354 | 64331778 |
Treatment failure | 26.87 | 14.15 | 129 | 34471 | 116687 | 64347445 |
Lung diffusion test decreased | 26.76 | 14.15 | 13 | 34587 | 1183 | 64462949 |
Body temperature decreased | 26.63 | 14.15 | 49 | 34551 | 25879 | 64438253 |
Oropharyngeal pain | 26.43 | 14.15 | 106 | 34494 | 88761 | 64375371 |
Renal pain | 26.24 | 14.15 | 25 | 34575 | 6949 | 64457183 |
Bronchopulmonary aspergillosis allergic | 25.77 | 14.15 | 14 | 34586 | 1608 | 64462524 |
Confusional state | 25.26 | 14.15 | 65 | 34535 | 261079 | 64203053 |
Drug tolerance | 25.18 | 14.15 | 23 | 34577 | 6062 | 64458070 |
Rheumatoid lung | 25.13 | 14.15 | 16 | 34584 | 2463 | 64461669 |
Pyrexia | 24.68 | 14.15 | 187 | 34413 | 558457 | 63905675 |
Stiff person syndrome | 24.48 | 14.15 | 8 | 34592 | 254 | 64463878 |
Drug ineffective | 24.46 | 14.15 | 606 | 33994 | 839641 | 63624491 |
Occupational exposure to product | 24.40 | 14.15 | 10 | 34590 | 608 | 64463524 |
Disease progression | 24.38 | 14.15 | 24 | 34576 | 141656 | 64322476 |
Central obesity | 24.35 | 14.15 | 13 | 34587 | 1442 | 64462690 |
Abdominal pain upper | 24.30 | 14.15 | 169 | 34431 | 174861 | 64289271 |
Incorrect product administration duration | 24.20 | 14.15 | 28 | 34572 | 9730 | 64454402 |
Rheumatoid arthritis | 23.62 | 14.15 | 160 | 34440 | 164134 | 64299998 |
Crepitations | 23.58 | 14.15 | 25 | 34575 | 7890 | 64456242 |
Therapeutic reaction time decreased | 23.49 | 14.15 | 14 | 34586 | 1918 | 64462214 |
Pain in extremity | 23.39 | 14.15 | 257 | 34343 | 302828 | 64161304 |
Peak expiratory flow rate abnormal | 23.32 | 14.15 | 6 | 34594 | 79 | 64464053 |
Abdominal pain | 23.25 | 14.15 | 263 | 34337 | 312112 | 64152020 |
Airway remodelling | 23.24 | 14.15 | 7 | 34593 | 169 | 64463963 |
Pain | 23.14 | 14.15 | 421 | 34179 | 553090 | 63911042 |
Electrocardiogram QT prolonged | 22.99 | 14.15 | 7 | 34593 | 79441 | 64384691 |
Lactic acidosis | 22.77 | 14.15 | 3 | 34597 | 61407 | 64402725 |
Musculoskeletal disorder | 22.51 | 14.15 | 37 | 34563 | 17869 | 64446263 |
Urine odour abnormal | 22.40 | 14.15 | 20 | 34580 | 5116 | 64459016 |
Allergy to chemicals | 22.39 | 14.15 | 11 | 34589 | 1026 | 64463106 |
Blood test abnormal | 22.34 | 14.15 | 31 | 34569 | 12912 | 64451220 |
Gastrointestinal motility disorder | 22.26 | 14.15 | 20 | 34580 | 5159 | 64458973 |
Renal failure | 22.11 | 14.15 | 170 | 34430 | 181518 | 64282614 |
Delirium | 22.11 | 14.15 | 5 | 34595 | 69189 | 64394943 |
Pulmonary embolism | 21.68 | 14.15 | 28 | 34572 | 146328 | 64317804 |
Lung opacity | 21.44 | 14.15 | 16 | 34584 | 3183 | 64460949 |
Blood pressure systolic decreased | 21.35 | 14.15 | 25 | 34575 | 8795 | 64455337 |
Blood pressure diastolic abnormal | 21.25 | 14.15 | 29 | 34571 | 11888 | 64452244 |
International normalised ratio increased | 21.13 | 14.15 | 8 | 34592 | 79159 | 64384973 |
Forced vital capacity decreased | 21.12 | 14.15 | 12 | 34588 | 1504 | 64462628 |
Chromaturia | 21.08 | 14.15 | 41 | 34559 | 22570 | 64441562 |
Patella fracture | 20.67 | 14.15 | 12 | 34588 | 1566 | 64462566 |
Infusion related reaction | 20.64 | 14.15 | 155 | 34445 | 164312 | 64299820 |
Device dependence | 20.60 | 14.15 | 5 | 34595 | 51 | 64464081 |
Blood pressure diastolic increased | 20.45 | 14.15 | 27 | 34573 | 10725 | 64453407 |
Bradycardia | 20.37 | 14.15 | 20 | 34580 | 118199 | 64345933 |
Carcinoid tumour | 20.28 | 14.15 | 8 | 34592 | 440 | 64463692 |
Abnormal faeces | 20.16 | 14.15 | 20 | 34580 | 5839 | 64458293 |
Terminal insomnia | 20.14 | 14.15 | 10 | 34590 | 954 | 64463178 |
Hypotension | 20.05 | 14.15 | 121 | 34479 | 380853 | 64083279 |
Renal neoplasm | 19.96 | 14.15 | 12 | 34588 | 1669 | 64462463 |
Heart rate decreased | 19.96 | 14.15 | 70 | 34530 | 54997 | 64409135 |
Intentional overdose | 19.57 | 14.15 | 12 | 34588 | 89932 | 64374200 |
Anaemia | 19.55 | 14.15 | 121 | 34479 | 378559 | 64085573 |
Hypokalaemia | 19.46 | 14.15 | 22 | 34578 | 121881 | 64342251 |
Chronic kidney disease-mineral and bone disorder | 19.26 | 14.15 | 8 | 34592 | 503 | 64463629 |
Metabolic acidosis | 19.23 | 14.15 | 7 | 34593 | 70951 | 64393181 |
Heart rate increased | 19.21 | 14.15 | 104 | 34496 | 98571 | 64365561 |
Seizure | 19.00 | 14.15 | 38 | 34562 | 166854 | 64297278 |
Bone density decreased | 18.94 | 14.15 | 25 | 34575 | 9927 | 64454205 |
Ear infection | 18.92 | 14.15 | 40 | 34560 | 23364 | 64440768 |
Bladder disorder | 18.78 | 14.15 | 22 | 34578 | 7745 | 64456387 |
Therapeutic product effect incomplete | 18.77 | 14.15 | 107 | 34493 | 103375 | 64360757 |
Hyperparathyroidism secondary | 18.70 | 14.15 | 13 | 34587 | 2317 | 64461815 |
Respiratory arrest | 18.69 | 14.15 | 3 | 34597 | 52982 | 64411150 |
Wheezing | 18.53 | 14.15 | 89 | 34511 | 80490 | 64383642 |
Gastritis fungal | 18.46 | 14.15 | 6 | 34594 | 187 | 64463945 |
Erythema of eyelid | 18.23 | 14.15 | 12 | 34588 | 1956 | 64462176 |
Hypoglycaemia | 18.20 | 14.15 | 13 | 34587 | 89879 | 64374253 |
Gastric disorder | 18.17 | 14.15 | 45 | 34555 | 29152 | 64434980 |
Blood pressure increased | 18.05 | 14.15 | 156 | 34444 | 172396 | 64291736 |
Muscle strain | 17.83 | 14.15 | 22 | 34578 | 8172 | 64455960 |
Knee deformity | 17.74 | 14.15 | 9 | 34591 | 899 | 64463233 |
Systemic lupus erythematosus | 17.39 | 14.15 | 10 | 34590 | 77602 | 64386530 |
Product use issue | 17.38 | 14.15 | 140 | 34460 | 151575 | 64312557 |
Medication error | 17.24 | 14.15 | 3 | 34597 | 49963 | 64414169 |
Therapeutic response shortened | 17.01 | 14.15 | 24 | 34576 | 10146 | 64453986 |
Septic shock | 16.86 | 14.15 | 19 | 34581 | 105418 | 64358714 |
Echocardiogram abnormal | 16.79 | 14.15 | 11 | 34589 | 1778 | 64462354 |
Lung diffusion disorder | 16.79 | 14.15 | 5 | 34595 | 116 | 64464016 |
Mental status changes | 16.63 | 14.15 | 6 | 34594 | 61156 | 64402976 |
Dyspepsia | 16.56 | 14.15 | 86 | 34514 | 80226 | 64383906 |
Gamma-glutamyltransferase increased | 16.55 | 14.15 | 3 | 34597 | 48507 | 64415625 |
Pemphigus | 16.42 | 14.15 | 6 | 34594 | 60695 | 64403437 |
Respiratory distress | 16.29 | 14.15 | 4 | 34596 | 52327 | 64411805 |
Injection site oedema | 16.27 | 14.15 | 9 | 34591 | 1071 | 64463061 |
Suicide attempt | 16.12 | 14.15 | 9 | 34591 | 70998 | 64393134 |
Oral discomfort | 15.82 | 14.15 | 21 | 34579 | 8385 | 64455747 |
Heart rate irregular | 15.76 | 14.15 | 41 | 34559 | 27372 | 64436760 |
Migraine | 15.71 | 14.15 | 71 | 34529 | 62606 | 64401526 |
Neck pain | 15.65 | 14.15 | 70 | 34530 | 61463 | 64402669 |
Dry throat | 15.65 | 14.15 | 18 | 34582 | 6214 | 64457918 |
Tubulointerstitial nephritis | 15.53 | 14.15 | 44 | 34556 | 30865 | 64433267 |
Cardiac failure congestive | 15.50 | 14.15 | 29 | 34571 | 130551 | 64333581 |
Haematocrit decreased | 15.48 | 14.15 | 5 | 34595 | 54650 | 64409482 |
Influenza | 15.45 | 14.15 | 104 | 34496 | 106427 | 64357705 |
Unresponsive to stimuli | 15.40 | 14.15 | 4 | 34596 | 50389 | 64413743 |
Ascites | 15.36 | 14.15 | 7 | 34593 | 61994 | 64402138 |
Pharyngitis streptococcal | 15.32 | 14.15 | 21 | 34579 | 8647 | 64455485 |
Nasal congestion | 15.27 | 14.15 | 68 | 34532 | 59590 | 64404542 |
Mobility decreased | 15.07 | 14.15 | 88 | 34512 | 85752 | 64378380 |
Humidity intolerance | 15.06 | 14.15 | 6 | 34594 | 339 | 64463793 |
Thoracic operation | 15.00 | 14.15 | 5 | 34595 | 169 | 64463963 |
Glossodynia | 14.98 | 14.15 | 8 | 34592 | 64688 | 64399444 |
Renal mass | 14.64 | 14.15 | 12 | 34588 | 2735 | 64461397 |
Lung perforation | 14.55 | 14.15 | 4 | 34596 | 69 | 64464063 |
Blood alkaline phosphatase increased | 14.50 | 14.15 | 6 | 34594 | 56273 | 64407859 |
Renal haemangioma | 14.40 | 14.15 | 3 | 34597 | 14 | 64464118 |
Flail chest | 14.33 | 14.15 | 4 | 34596 | 73 | 64464059 |
Stomatitis | 14.23 | 14.15 | 23 | 34577 | 109582 | 64354550 |
Acute myocardial infarction | 14.22 | 14.15 | 10 | 34590 | 69708 | 64394424 |
Pneumonia aspiration | 14.21 | 14.15 | 7 | 34593 | 59264 | 64404868 |
None
Source | Code | Description |
---|---|---|
ATC | A02BC06 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors |
FDA MoA | N0000000147 | Proton Pump Inhibitors |
FDA EPC | N0000175525 | Proton Pump Inhibitor |
MeSH PA | D000897 | Anti-Ulcer Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D054328 | Proton Pump Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Peptic ulcer | indication | 13200003 | DOID:750 |
Erosive esophagitis | indication | 40719004 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Maintenance of Healing Erosive Esophagitis | indication | ||
Duodenal ulcer disease | off-label use | 51868009 | DOID:1724 |
Zollinger-Ellison syndrome | off-label use | 53132006 | DOID:0050782 |
Gastric ulcer | off-label use | 397825006 | DOID:10808 |
Duodenal Ulcer due to H. Pylori | off-label use | ||
Maintenance of Healing Duodenal Ulcer | off-label use | ||
NSAID-Induced Gastric Ulcer | off-label use | ||
Prevention of NSAID-Induced Gastric Ulcer | off-label use | ||
Pathological Gastric Hypersecretory Condition | off-label use | ||
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Fracture of bone | contraindication | 125605004 | |
Hypomagnesemia | contraindication | 190855004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.23 | acidic |
pKa2 | 3.35 | Basic |
pKa3 | 2.72 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
30MG | DEXILANT SOLUTAB | TAKEDA PHARMS USA | N208056 | Jan. 26, 2016 | DISCN | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
30MG | DEXILANT SOLUTAB | TAKEDA PHARMS USA | N208056 | Jan. 26, 2016 | DISCN | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | ORAL | 6664276 | Jan. 30, 2023 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD) |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD) |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8784885 | Oct. 15, 2023 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 8173158 | March 17, 2030 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
30MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9233103 | March 5, 2032 | USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS |
60MG | DEXILANT | TAKEDA PHARMS USA | N022287 | Jan. 30, 2009 | RX | CAPSULE, DELAYED RELEASE | ORAL | 9233103 | March 5, 2032 | USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Potassium-transporting ATPase | Transporter | INHIBITOR | CHEMBL | CHEMBL | |||||
Cytosolic endo-beta-N-acetylglucosaminidase | Enzyme | IC50 | 4.60 | CHEMBL | |||||
Sterile alpha and TIR motif-containing protein 1 | Unclassified | IC50 | 5.48 | CHEMBL |
ID | Source |
---|---|
4028570 | VUID |
N0000189452 | NUI |
D08903 | KEGG_DRUG |
313640-86-7 | SECONDARY_CAS_RN |
4028570 | VANDF |
C2348248 | UMLSCUI |
CHEBI:135931 | CHEBI |
CHEMBL1201863 | ChEMBL_ID |
D064748 | MESH_DESCRIPTOR_UI |
DB05351 | DRUGBANK_ID |
5487 | IUPHAR_LIGAND_ID |
8524 | INN_ID |
UYE4T5I70X | UNII |
9578005 | PUBCHEM_CID |
816346 | RXNORM |
160770 | MMSL |
172755 | MMSL |
26184 | MMSL |
356045 | MMSL |
d07395 | MMSL |
012953 | NDDF |
441863009 | SNOMEDCT_US |
442540007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-703 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-703 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-704 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-704 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4374 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA | 32 sections |
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5944 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA AUTHORIZED GENERIC | 32 sections |
Dexlansoprazole delayed release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5956 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA AUTHORIZED GENERIC | 32 sections |
Kapidex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5998 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA | 16 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6152 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA | 31 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-5154 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA | 31 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-171 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA | 33 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-171 | CAPSULE, DELAYED RELEASE | 30 mg | ORAL | NDA | 33 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-175 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA | 33 sections |
Dexilant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-175 | CAPSULE, DELAYED RELEASE | 60 mg | ORAL | NDA | 33 sections |